CGTXCognition Therapeutics Inc
CGTX
Cognition Therapeutics Inc3,990
Mkt Cap
$112.59MVolume
843,586.0052W High
$3.8352W Low
$0.2223PE Ratio
-3.72CGTX Fundamentals
Price
$1.28Prev Close
$1.26Open
$1.2750D MA
$1.06Beta
1.81Avg. Volume
1.19MEPS (Annual)
-$0.3228P/B
3.32Rev/Employee
$0.00$61.87
Cognition Therapeutics (CGTX) to Release Earnings on Wednesday
Cognition Therapeutics (NASDAQ:CGTX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-cognition-therapeutics-inc-stock...
MarketBeat·3d ago
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Moderate Buy" by Analysts
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the four analysts that are covering the firm, MarketBeat reports. One research...
MarketBeat·11d ago
Insider Buying: Cognition Therapeutics (NASDAQ:CGTX) CEO Acquires 9,175 Shares of Stock
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares of the company's stock in a transaction dated Thursday, April 16th. The shares were acquired at an...
MarketBeat·11d ago
John Brendan Doyle Purchases 10,000 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CFO John Brendan Doyle bought 10,000 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average cost of $1.13 per share, with a total value of $11,300.00. Following the completion of...
MarketBeat·12d ago
Lisa Ricciardi Acquires 9,175 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi acquired 9,175 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The shares were purchased at an average price of $1.10 per share, with a total value of $10,092.50. Following the...
MarketBeat·12d ago
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans
Cognition Therapeutics (NASDAQ:CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage...
MarketBeat·19d ago
Q1 Earnings Forecast for CGTX Issued By HC Wainwright
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Cognition Therapeutics in a research report issued on Friday...
MarketBeat·1mo ago
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four research firms that are covering the stock, MarketBeat reports. One...
MarketBeat·1mo ago
Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital
Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of Cognition Therapeutics in a research report on Friday...
MarketBeat·1mo ago
Cognition Therapeutics Q4 Earnings Call Highlights
Cognition Therapeutics (NASDAQ:CGTX) used its fourth-quarter and full-year 2025 earnings call to outline a shift in development priorities for its lead candidate, zervimesine (CT-1812), with management saying it will now focus on pursuing a registration path in dementia with Lewy bodies (DLB) psycho...
MarketBeat·1mo ago
<
1
2
...
>